GenixPharmaceucticals Corporation Total Liabilities
GenixPharmaceucticals Corporation total liabilities. Based on the latest financial reports, GenixPharmaceucticals Corporation (GENX) has total liabilities worth CA$1.58 Million CAD (≈ $1.14 Million USD) as of April 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of GenixPharmaceucticals Corporation to measure how many days the company can operate on defensive assets alone.
Total Liabilities of GenixPharmaceucticals Corporation (2015–2025)
Total liabilities of GenixPharmaceucticals Corporation from 2015 to 2025. This chart illustrates how GenixPharmaceucticals Corporation's total liabilities have evolved over time, based on quarterly financial data.
GenixPharmaceucticals Corporation Competitors by Total Liabilities
The table below lists competitors of GenixPharmaceucticals Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MEMIONTEC HOLDINGS LTD
F:8900
|
Germany | €25.07 Million |
|
Ondine Biomedical Inc
LSE:OBI
|
UK | GBX12.17 Million |
|
IMAGE POWER S.A. ZY -10
F:7UQ
|
Germany | €280.97K |
|
Fort St James Nickel Corp
V:FTJ
|
Canada | CA$2.11 Million |
|
GOLDSTONE RES LTD. LS-01
F:GVL1
|
Germany | €13.63 Million |
|
VSee Health, Inc.
NASDAQ:VSEE
|
USA | $16.96 Million |
|
Gemfields Plc
LSE:GEM
|
UK | GBX206.14 Million |
|
Magic Empire Global Limited
NASDAQ:MEGL
|
USA | $4.61 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down GenixPharmaceucticals Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GENX current and non-current assets.
Liquidity & Leverage Metrics
GenixPharmaceucticals Corporation Total Liabilities Ratios Explained
GenixPharmaceucticals Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 47.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GenixPharmaceucticals Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GenixPharmaceucticals Corporation (2015–2025)
The table below shows the annual total liabilities of GenixPharmaceucticals Corporation from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | CA$1.47 Million ≈ $1.06 Million |
+19.66% |
| 2024-10-31 | CA$1.23 Million ≈ $888.86K |
-9.71% |
| 2023-10-31 | CA$1.36 Million ≈ $984.40K |
+29.17% |
| 2022-10-31 | CA$1.05 Million ≈ $762.10K |
+39.50% |
| 2021-10-31 | CA$755.19K ≈ $546.29K |
+54.16% |
| 2020-10-31 | CA$489.88K ≈ $354.37K |
+494.44% |
| 2019-10-31 | CA$82.41K ≈ $59.61K |
-24.50% |
| 2018-10-31 | CA$109.15K ≈ $78.96K |
-59.99% |
| 2017-10-31 | CA$272.80K ≈ $197.34K |
+300.95% |
| 2016-10-31 | CA$68.04K ≈ $49.22K |
-38.58% |
| 2015-10-31 | CA$110.78K ≈ $80.13K |
-- |
About GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral,… Read more